EXCLUSIVE: The U.K. drugmaker currently has five approved cancer medicines and a clinical-stage portfolio of about 15 assets.

By Bhanvi Satija and Sneha S K MADRID, Oct 26 (Reuters) - An experimental drug for a hard-to-treat bone cancer, being developed by Hansoh Pharmaceutical and GSK, helped patients live longer without ...

Oct 27 (Reuters) - The US FDA on Tuesday warned Amgen that a promotional video for its colorectal cancer drug was misleading ...

Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to disappear or shrink in an early-stage trial. J&J had gained access to the ...

By Bhanvi Satija MADRID, Oct 25 (Reuters) - AstraZeneca's experimental drug sone-ve helped patients with advanced stomach ...

Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and ...

AstraZeneca Plc’s experimental stomach cancer drug doubled the time patients survived in a late-stage trial, boosting ...

Johnson & Johnson (NYSE:JNJ) has presented Phase 1 clinical trial results for JNJ-6143, an investigational oral treatment for advanced prostate cancer, at the European Society for Medical Oncology ...

The new targeted therapy is designed to block KRAS, a protein that drives many pancreatic cancers, and its approval underscores the importance of clinical trials in advancing treatment options.

A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines' oral tablet daraxonrasib, branded as Rasonque, reduced ...

Bristol Myers Squibb reported that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trial ...